Pioglitazone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pioglitazone: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Pioglitazone is a thiazolidinedione (TZD)-class PPAR-γ agonist historically used as an insulin sensitizer in type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare INPPL1-related skeletal dysplasia, but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself notes no known biological link between the two conditions.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (no EU license text or original_indications entries available; Pioglitazone is generally classified as a type 2 diabetes mellitus therapy) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as data gap DG002, High severity). Based on general drug classification, Pioglitazone belongs to the thiazolidinedione (TZD) class, acting as a PPAR-γ agonist that improves insulin sensitivity and has been used clinically in type 2 diabetes management.
Opsismodysplasia, however, is a rare autosomal recessive skeletal dysplasia caused by mutations in INPPL1, affecting phosphoinositide signaling and bone growth — a pathway with no established connection to PPAR-γ agonism. The evidence pack’s own mechanistic assessment is explicit on this point: “與 PPAR-γ 通路無已知關聯，僅為 TxGNN 圖譜相似性預測，缺乏生物學合理性連結” (no known association with the PPAR-γ pathway; the prediction reflects only TxGNN graph-similarity output and lacks biological plausibility).
Given the absence of a coherent mechanistic rationale and the complete lack of clinical trials or literature (L5), this candidate should be treated as a preliminary algorithmic signal only — not a validated repurposing hypothesis warranting further investment at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Pioglitazone currently has no EU marketing authorizations on file in this evidence pack (market status: not marketed, 0 licenses recorded).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: a Blocking data gap — DG001, missing TFDA/regulatory drug label warnings and contraindications — prevents this candidate from entering Stage S1 safety review.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (opsismodysplasia, TxGNN score 99.59%) has zero supporting clinical trials or literature (L5), and the evidence pack’s own mechanistic review found no biological plausibility linking Pioglitazone’s PPAR-γ pathway to this rare skeletal disorder. In addition, a Blocking data gap (missing regulatory safety labeling) prevents entry into Stage S1 safety review.
To proceed, the following is needed:
- TFDA/regulatory drug label (warnings, contraindications) — resolves Blocking gap DG001
- Verified mechanism of action data via DrugBank API — resolves High-priority gap DG002
- Independent mechanistic or preclinical evidence directly connecting Pioglitazone to opsismodysplasia before further investment
- If exploring alternative candidates from this evidence pack, rank 9 (pancreatic agenesis, L4) has some literature support, though the rationale notes the cited studies are non-specific reviews of TZDs in general type 2 diabetes rather than disease-specific evidence, and the mechanism (insulin sensitization vs. absolute insulin deficiency) is potentially contradictory
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.